Grifols – AMBAR

Grifols has developed AMBAR, a plasmapheresis technique that infuses patients with human albumin and intravenous immunoglobin (IVIG) for the treatment of Alzheimer’s disease. The company’s hypothesis was that amyloid beta, the main driver of Alzheimer’s disease, binds to albumin in the brain, which can then be removed from the body.

The company’s results have confirmed that that this approach is valid, although it does not constitute a cure. Grifols reports that treated patients with moderate Alzheimer’s have experienced a 61% reduction in disease progression and a 71% reduction of symptoms, with positive results reported forboth moderate and mild Alzheimer’s.

Website: Trial Description, Results

Organizations: